CorePharma announced the launch of Methylphenidate HCl Tablets, the generic version of Novartis‘ Ritalin. CorePharma received final FDA approval for its Abbreviated New Drug Application (ANDA) on March 12, 2014.
Methylphenidate is indicated for the treatment of narcolepsy and attention deficit disorders. The mode of action in humans is not completely understood, but methylphenidate presumably activates the brain stem arousal system and cortex to produce its stimulant effect.
Methylphenidate HCl Tablets are available in 5mg, 10mg, and 20mg strengths.
For more information call (800) 850-2719 or visit CorePharma.com.